Chimeric antigen receptor (CAR) T-cell therapy has been used for the treatment of hematological malignancies, but oncologists have been using it less often due to the loss of therapeutic effectiveness ...

VANCOUVER, British Columbia, October 16, 2025--(BUSINESS WIRE)--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company ...

ATLANTA -- An antibody-drug conjugate (ADC) targeting CD22 achieved a high response rate and exceeded a prespecified survival goal in older patients with newly diagnosed acute lymphoblastic leukemia ...

Clinical Trials of ADCs for the Treatment of B-cell Malignancies Five ADCs targeting the B-lineage antigens CD22, CD19 and CD70 are currently in clinical trials for B-cell malignancies: inotuzumab ...

Philadelphia, January 4, 2022—Aberrant splicing of messenger RNAs encoding surface antigen CD22 leads to downregulation of this protein in pediatric B-lymphoblastic leukemia (B-ALL), rendering ...

Investigators found important differences that may help clinicians better understand how to manage toxicities associated with the therapy. The toxicity profile of chimeric antigen receptor (CAR) T ...

Tumor Grade Is Associated With Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study The frequency and intensity of antigen expression varies with ...

Ideally an MRD assay would also be applied to pretreatment/diagnostic samples, in order to ensure that each patient is suitable for monitoring with the specific assay ...

Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial Therapy consisted of a single-agent phase ...

PLEASANTON, Calif. & NANJING, China--(BUSINESS WIRE)--First sentence of release should read: "...has been accepted by the China National Medical Products Administration (NMPA)..." (instead of "...has ...